Results 181 to 190 of about 17,826,638 (304)

Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS‐like tyrosine kinase 3 (FLT3)‐mutated acute myeloid leukaemia patients: A multicentre real‐world study

British Journal of Haematology, EarlyView.
Summary Patients with relapsed or refractory acute myeloid leukaemia (r/r AML) harbouring FMS‐like tyrosine kinase 3 (FLT3) mutations generally have poor prognosis and limited treatment options. The second‐generation FLT3 inhibitor gilteritinib provides better disease control compared to standard relapse therapies and was approved based on two ...
Desiree Kunadt, Sven Zukunft, Christoph Röllig, Stephan Metzelder, Andreas Burchert, Eva Wagner‐Drouet, Oliver Kriege, Christoph Schliemann, Matthias Stelljes, Julian Ronnacker, Wolfgang Bethge, Jan Frederic Weller, Björn Steffen, Gesine Bug, Khouloud Kouidri, Claudia Baldus, Lars Fransecky, Elisa Sala, Uwe Platzbecker, Klaus Metzeler, Sabine Kayser, Inken Hilgendorf, Andreas Hochhaus, Tim H. Brümmendorf, Edgar Jost, Anna Dorottya Doleschall, Thomas Schroeder, Jennifer Kaivers, Lambros Kordelas, Udo Holtick, Julia M. Unglaub, Tim Sauer, Paul Sebastian Jäger, Guido Kobbe, Elena Stauffer, Johanna Tischer, Tobias Herold, Normann Steiner, David Nachbaur, Nicolaus Kröger, Jochen J. Frietsch, Sabrina Kraus, Hermann Einsele, Mathias Hänel, Judith Schaffrath, William Krüger, Anne Brandenburg, Tobias A. W. Holderried, Laura Reinhardt, Markus Maulhardt, Christian Thiede, Martin Bornhäuser, Johannes Schetelig, Jan M. Middeke, Friedrich Stölzel, for the German Cooperative Transplant Study Group and Study Alliance Leukemia (SAL)   +55 more
wiley   +1 more source

Second primary cancers in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia—cumulative burden without generalized excess cancer risk

British Journal of Haematology, EarlyView.
Summary Second primary cancers (SPCs) are a survivorship concern in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia (LPL/WM), but estimates may be influenced by competing mortality and surveillance. We assessed cumulative incidence, relative risk and predictors of SPCs. We studied 521 patients diagnosed with LPL/WM in Region Zealand, Denmark,
Lars Munksgaard, Lars Moeller Pedersen, Lise Mette Rahbek Gjerdrum   +2 more
wiley   +1 more source

Timing matters: Impact of covalent BTK inhibitor dose modifications on outcomes in chronic lymphocytic leukemia/small lymphocytic leukemia-A 7-year real-world study. [PDF]

Cancer
Zhang J, Luo J, Shen X, Ren J, Liu W, Chen L, Jiang L, Weng X, Wang J, Mi JQ.   +9 more
europepmc   +1 more source

Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma: Phase 1b dose‐escalation study

British Journal of Haematology, EarlyView.
Summary Glofitamab was investigated with obinutuzumab/rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (G/R‐CHOP) in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma (B‐NHL) who had ≥1 prior obinutuzumab/rituximab‐containing therapy (NCT03467373). The primary end‐point was to determine the optimal biological dose of
William Townsend, Nilanjan Ghosh, Martin Hutchings, Michael Dickinson, Monica Tani, Armando Santoro, Michael Crump, Amitkumar Mehta, Reinhard Marks, Martin Weisser, Martin Barrett, Chun Wu, Derrick Kaufman, Katharina Lechner, Pauline Baumlin, Pontus Lundberg, Max S. Topp   +16 more
wiley   +1 more source

Limited evidence for causal effects of circulating inflammatory cytokines on the risk of selected hematologic malignancies: a two-sample Mendelian randomization study. [PDF]

Blood Res
Zhang H, Zhang L, Zhao D, Ma B, Wang J, Liu X, Yin W, Shen Y, Yang L, Dong W, Wang C.   +10 more
europepmc   +1 more source

Minimal residual disease–guided ibrutinib and venetoclax in patients with chronic lymphocytic leukaemia and complex karyotype

British Journal of Haematology, EarlyView.
Minimal residual disease (MRD)–guided ibrutinib and venetoclax (IVen) achieved durable remissions and high undetectable MRD (uMRD) rates in patients with high‐risk chronic lymphocytic leukaemia (CLL). Compared with historical ibrutinib monotherapy, IVen was associated with improved progression‐free and overall survival despite presence of complex ...
Maria Kislova, Elena Dmitrieva, Elena Naumova, Margarita Pochtar, Svetlana Lugovskaya, Yury Kobzev, Alla Loban, Maria Gladysheva, Tatiana Obukhova, Bella Biderman, Andrey Sudarikov, Egor Volchkov, Maria Ivanova, Vadim Ptushkin, Andrea Visentin, Eugene Nikitin   +15 more
wiley   +1 more source

Hypereosinophilic syndrome with Löffler endocarditis and multiple cerebral infarctions in a patient with a CLL-phenotype clonal B-cell population: a case report. [PDF]

Front Cardiovasc Med
Wang H, Zhu F, Hu H.
europepmc   +1 more source

Albumin activates the AKT signalling pathway and protects B-chronics lymphocytic leukemia cells from chlorambucil- and radiation-induced apoptosis [PDF]

, 2002
Palmqvist, L, Jones, DT, Ganeshaguru, K, Prentice, HG, Mehta, AB, Anderson, RJ, Bruckdorfer, KR, Jackson, TR, Low, SY, Wickremasinghe, RG, Hoffbrand, AV   +10 more
core  

Trends and socio‐economic disparities in chronic lymphocytic leukaemia 2014–2022: An England‐wide cohort study from the UNCOVER group

British Journal of Haematology, EarlyView.
Summary To re‐evaluate chronic lymphocytic leukaemia (CLL) epidemiology in the era of modern therapy, data were extracted from the English National Cancer Registration Dataset (NCRD). A total of 34 427 consecutive diagnoses of CLL were recorded (2014–2022), the largest European dataset on record.
Temitope Erinfolami, Amelia Fisher, Indrani Karpha, Yeong Lim, Nurunnahar Akter, Toyyib Abdulkareem, Brogan Johnston, Catrin Tudur Smith, Hilary Lindsay, Shaun Bowden, Debbie Yates, Lelia Duley, Renata Walewska, Stella Williams, David Allsup, Nagesh Kalakonda, Mark Bishton, Andrew Pettitt, Nicolas Martinez‐Calle   +18 more
wiley   +1 more source

Concurrent CML and MBL in a COPD patient: a case of collision hematologic malignancies and opportunistic infection. [PDF]

Front Med (Lausanne)
Zhang L, Zhang MY, Zhou CS, Ci XY, Zhu LY, Hu QL, Qi ZR, Fu S, Li ZJ.   +8 more
europepmc   +1 more source